title: Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score.
abstract: OBJECTIVE
  We evaluated survival outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for clinical T2 renal masses (cT2RM) controlling for R.E.N.A.L. nephrometry score.
  
  
  METHODS
  A two-centre study comprised of 202 patients with cT2RM who underwent RN (122) or PN (80) between July 2002 and June 2012 (median follow-up 41.5 months). Kaplan-Meier analysis compared overall survival (OS), cancer-specific survival (CSS) and progression-free survival (PFS) among the entire cohort and within categories of R.E.N.A.L. nephrometry score of ≥10 and <10. Association between procedure and PFS and OS was analysed using Cox-proportional hazard.
  
  
  RESULTS
  There were no significant differences between PN and RN in clinical T stage and R.E.N.A.L. nephrometry scores. For RN and PN, the 5-year PFS was 69.8% and 79.9% (P = 0.115), CSS was 82.5% and 86.7% (P = 0.407), and OS was 80% and 83.3% (P = 0.291). Cox regression showed no association between RN vs PN and PFS; a R.E.N.A.L. nephrometry score of ≥10 was associated with a shorter PFS (hazard ratio 6.69, P = 0.002). Kaplan-Meier analysis for RN vs PN showed no difference in PFS for entire cohort or within the R.E.N.A.L. nephrometry score categories of ≥10 and <10. The PFS was better for those with R.E.N.A.L nephrometry scores of <10 vs ≥10 (P < 0.001) and for cT2a vs cT2b tumours (P = 0.012). OS was no different between cT2a and cT2b tumours; patients with R.E.N.A.L. nephrometry scores of ≥10 were more likely to die from disease (P < 0.001) or any cause (P < 0.001) vs those with R.E.N.A.L. nephrometry scores of <10.
  
  
  CONCLUSIONS
  PN may be oncologically effective for cT2RM. A R.E.N.A.L nephrometry score of ≥10 is negatively associated with OS among cT2RM compared with a score of <10 and provides additional risk assessment beyond clinical T stage. Further follow-up and prospective randomised investigation is requisite to confirm efficacy of PN for cT2RM.
authors.affiliation: Department of Urology, UC San Diego Health System, La Jolla, CA, USA.
authors.forename: Ryan P
authors.initials: RP
authors.lastname: Kopp
authors.forename: Reza
authors.initials: R
authors.lastname: Mehrazin
authors.forename: Kerrin L
authors.initials: KL
authors.lastname: Palazzi
authors.forename: Michael A
authors.initials: MA
authors.lastname: Liss
authors.forename: Ramzi
authors.initials: R
authors.lastname: Jabaji
authors.forename: Hossein S
authors.initials: HS
authors.lastname: Mirheydar
authors.forename: Hak J
authors.initials: HJ
authors.lastname: Lee
authors.forename: Nishant
authors.initials: N
authors.lastname: Patel
authors.forename: Fuad
authors.initials: F
authors.lastname: Elkhoury
authors.forename: Anthony L
authors.initials: AL
authors.lastname: Patterson
authors.forename: Ithaar H
authors.initials: IH
authors.lastname: Derweesh
mesh_terms: D000368:Aged; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods*; D015996:Survival Rate; D016896:Treatment Outcome
keywords: R.E.N.A.L. nephrometry; Stage 2; carcinoma; disease-free survival; nephrectomy; progression-free survival; renal cell